British pharmaceutical giant GSK announced on Monday that its cancer drug Jemperli has achieved overall survival in a Phase III trial for patients with primary advanced or recurrent endometrial cancer. The drug, used in conjunction with chemotherapy, has shown promising results in the most common gynecologic cancer, which records 417,000 new cases globally each year.
Jemperli (dostarlimab) was developed by AnaptysBio (NASDAQ:ANAB) and acquired through the TESARO acquisition. The Phase III trial involved adult patients at various stages of endometrial cancer. The trial first combined dostarlimab with chemotherapy before moving on to use the drug as a standalone treatment. The placebo group was initially given a combination of placebo and chemotherapy before continuing with just the placebo.
The statistically significant results from Part 1 of the trial demonstrated substantial benefits to patients. The trial had two primary objectives: overall survival and progression-free survival (PFS), both of which were met.
Jemperli is already approved as a second-line option in the U.S. and UK for treating certain types of this cancer. The recent results further strengthen the efficacy profile of Jemperli, potentially opening up possibilities for its use as a first-line treatment option for endometrial cancer.
InvestingPro Insights
The recent success of GSK's cancer drug Jemperli is a testament to the company's ability to yield high returns on invested capital, a key observation noted in our InvestingPro Tips. This, coupled with the fact that three analysts have revised their earnings upwards for the upcoming period, suggests a strong financial outlook for GSK.
From our real-time InvestingPro data, GSK's market cap stands at a robust 71.5B USD, with a P/E Ratio of 3.81. The company has also demonstrated strong revenue growth, with a rate of 5.43% over the last twelve months as of Q2 2023.
For those interested in diving deeper into GSK's financial performance and future prospects, our InvestingPro product offers 11 additional InvestingPro Tips, providing a comprehensive analysis of the company's performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.